Dr. Alan Cookson, CEO is a co-founder of the Company. He brings substantial experience of the pharmaceutical industry both from his career in the Ares-Serono group in Europe and the United States where he held positions of increasing responsibility including VP, Research and Bus Development, and as founder and CEO of two start-up companies. Until recently Alan specialised in encouraging and managing the commercial exploitation of academic research innovation, and led a number of life sciences licensing projects for the University of Geneva, including the project that led to the formation of Apidel.
Prof. Robert Gurny, CSO is co-founder of the Company and co-inventor of the technologies, previously Professor at University of Geneva, he served as President of the Department of Pharmaceutical Sciences. Robert enjoys an outstanding reputation as a drug delivery scientist who brings a lot of realism to his creativity and has successfully managed many substantial industry/university collaborations with mid-cap and big pharma. He is also the author of more than 200 peer reviewed articles, several books and more than 80 abstracts of presentations as well as the inventor of over 40 patent applications. Robert has received numerous prestigious awards such as the Merck Award (1994), the APV Prize (1995), the Phoenix Award (1996) and the Roger Barré prize (1999). For many years Robert was the Editor-in-Chief of the European Journal of Pharmaceutics and Biopharmaceutics.
Dr. Michael Möller, Technical Director is co-founder of the Company and co-inventor of the technologies; he is an organic research chemist with extensive international experience gathered at Philips University, Marburg, Germany, Okayama University of Science, Japan, Stanford University, USA and the IBM Almaden Research Center, USA; Michael’s expertise in designing, characterizing and synthesizing novel molecules both with specific material applications and for assimilation into useful nanostructures led him to join the School of Pharmacy of the University of Geneva where pioneering work on novel molecules and structures as drug delivery mechanisms has been made. The combination of expertise in chemistry, synthesis and practical application in drug delivery has enabled the establishment of key intellectual property leading directly to the formation of Apidel.
Victoria Sarraf, Alliance Manager is a licensed Pharmacist (MSc. Pharm., Federal Diploma) and is post-graduated in Management from the Business School of University of Lausanne (HEC). She joined first Vifor Pharma (Galenica Group), where she held positions of increasing responsibility including Head of Marketing. Launching and building a lead analgesic brand on the Swiss market was part of her major achievements. She then acquired substantial experience in Business Development, negotiating a number of new drug entity licensing agreements with global players at Debiopharm International and managing, for several years, a worldwide alliance for a blockbuster oncology product. She joined Apidel in March 2014 to contribute to building new partnerships, strengthening Apidel’s existing alliances and developing in-house projects to bring future high-potential new products on the market.
Dr. Doris Gabriel, R&D Head of the Laboratories is a PhD pharmacist, who following her training at the Universities of Bern, Basel and Geneva, has engaged in post-doctoral research in biophotonics at the EPFL in Lausanne, and most recently in drug delivery at the Massachusetts Institute of Technology / Harvard Medical School. Dr. Gabriel brings substantial relevant research experience in pharmaceutical formulation and drug delivery, and joined Apidel as R&D Project Leader in October 2012. Her responsibilities include the set-up and supervision of Apidel’s laboratory facilities, as well as managing key research projects and delivering research results for Apidel’s partners.